The Role of Anti-Thymocyte Globulin (ATG) in Patients with AML Transplanted in CR1 from Sibling and Unrelated Donors with or without Measurable Residual Disease (MRD) at the Time of Allogeneic Stem Cell Transplantation:a Study on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) - UTU Tutkimustietojärjestelmä

A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

The Role of Anti-Thymocyte Globulin (ATG) in Patients with AML Transplanted in CR1 from Sibling and Unrelated Donors with or without Measurable Residual Disease (MRD) at the Time of Allogeneic Stem Cell Transplantation:a Study on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Tekijät: Arnon Nagler, Myriam Labopin, Gerard Socié, Anne Huynh, Maija Itälä-Remes, Eric Deconinck,Ibrahim Yakoub-Agha,
Jean-Yves Cahn, Jean Henri Bourhis, Hélène Labussière-Wallet,Sylvain Chantepie, Jordi Esteve, Mohamad Mohty

Kustantaja: Kluge Carden Jennings Pub. Co.

Julkaisuvuosi: 2019

Journal: Biology of Blood and Marrow Transplantation

eISSN: 1523-6536

DOI: https://doi.org/10.1016/j.bbmt.2018.12.126

Verkko-osoite: 10.1016/j.bbmt.2018.12.126